Skip to main content
OpenTrials

Clinical trial condition

Infection, Human Immunodeficiency Virus

Explore clinical trials studying Infection, Human Immunodeficiency Virus. Study availability and eligibility vary by location and protocol.

107 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Infection, Human Immunodeficiency Virus trial results

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Long Beach, California, United States
View all 50 locations
View Trial Details
Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
View all 90 locations
View Trial Details
Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site San Francisco, California, United States
View all 105 locations
View Trial Details
Completed

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

NCT00071760

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Jacksonville, Florida, United States
  • GSK Investigational Site Durham, North Carolina, United States
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Mexico City, Mexico
View all 15 locations
View Trial Details
Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Ft. Pierce, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
View all 90 locations
View Trial Details
Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

NCT01231516

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Bakersfield, California, United States
View all 180 locations
View Trial Details

Related conditions